OCU200
Asset
Fusion protein targeting integrins to treat macular edema.
- Stage
- Phase 1
- Modality
- Protein or enzyme
- Target
- Not known
- 2
- Indications
- 1
- Trial
- 1
- Developer
Trial NCT05802329 is still running. Trial NCT05802329 updated in its registry on Jul 31, 2026. clinicaltrials.gov
Indications
2Center-involved diabetic macular edema
Phase 1, Recruiting, NCT05802329, clinicaltrials.gov, Oct 31, 2026
Diabetic macular edema
Phase 1, Recruiting, NCT05802329, clinicaltrials.gov, Oct 31, 2026
In the full profile
- Owner and partners1
- Trials1
- Competitors7
Every asset’s record: target, stage, trials and the evidence behind it.